Skip to content

AI-Powered Forecasts for Biotech Investors

Home
Tools
About
Join ScanScor
Log In
- Panel

ScanScor

The AI Biotech Breakout Prediction Strategy

ScanScor

The AI Biotech Breakout Prediction Strategy

Predictions
Scores
News Stream

dilution risk

AI Biomed Predictions

MBRX – Mid-2026 AML unblinding could redefine tiny-cap MBRX valuation

ScanScor Admin / April 16, 2026

Search

Tools

Predictions
Scores
News Stream

Recent Comments

Recent Comments

1 day ago EQ – Equillium Set for Brea... – For EQ, I would separate three different things: Is the ... by ScanScor Admin
2 days ago JAGX – Jaguar Health Poised... – This is not a postmortem. It is more like a prognosis. M... by ScanScor Admin
2 weeks ago HOTH – Promising Therapeuti... – This was not a crazy prediction. It was a vulnerable micr... by ScanScor Admin
3 weeks ago MEIP – MEI Pharma Poised fo... – LITS (formerly MEIP) is not a viable biotech candidate f... by ScanScor Admin
3 weeks ago DRRX – Durect Set to Transf... – DURECT was acquired by Bausch Health, the merger closed b... by ScanScor Admin

Recent Posts

KROS – Keros faces make-or-break DMD launch window in Q2
MBRX – Mid-2026 AML unblinding could redefine tiny-cap MBRX valuation
KRRO – Korro’s next AATD nomination may reignite platform-belief rally
NRXP – Summer FDA Ketamine Decision Could Reawaken NRXP Speculation
BIVI – BioVie’s next real test is the mid-2026 Parkinson’s readout

ScanScor empowers traders and investors with instant
AI-driven access to trusted intelligence.

🧠 Powered by real-time AI
🔍 Trained to find the moment before it moves

Terms and Conditions
About
Join the ScanScor Revolution

Disclaimer: ScanScor provides research and educational information only. Nothing on this site is financial advice or a recommendation to buy or sell securities. ScanScor does not provide forecasts or guarantee any outcomes. Past performance is not indicative of future results.

Copyright © 2026 ScanScor

Best viewed on desktop. Mobile optimization coming soon.

Scroll to Top